SRL
CRSP icon

Scientech Research LLC’s CRISPR Therapeutics CRSP Stock Holding History

Scientech Research LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,337
Closed -$332K – 530
2025
Q4 		$332K Buy
+6,337
New +$380K 0.21% 175
2025
Q3 		– Sell
-11,445
Closed -$557K – 638
2025
Q2 		$557K Buy
+11,445
New +$443K 0.14% 306
2024
Q4 		– Sell
-9,638
Closed -$453K – 629
2024
Q3 		$453K Sell
9,638
-14,685
-60% -$745K 0.09% 391
2024
Q2 		$1.31M Buy
24,323
+15,686
+182% +$907K 0.27% 122
2024
Q1 		$589K Buy
+8,637
New +$618K 0.31% 92

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Scientech Research LLC's CRSP Position: Q1 2026 in Review

Scientech Research LLC sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 6,337 shares — an estimated $332K sold.

Scientech Research LLC first reported a position in CRSP in Q1 2024 and held it in 5 quarters. The position peaked at $1.31M in Q2 2024. 492 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Scientech Research LLC reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Scientech Research LLC sold 6,337 CRISPR Therapeutics shares in Q1 2026, an estimated $332K.
  • Scientech Research LLC first reported a position in CRISPR Therapeutics in Q1 2024 and held it in 5 quarters.
  • Scientech Research LLC's CRISPR Therapeutics position peaked at $1.31M in Q2 2024.
  • 492 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Scientech Research LLC's 13F filing for Q1 2026, filed 15 May 2026.